Risk of cancer in children and young adults conceived by assisted reproductive technology.


Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 30 05 2018
revised: 06 12 2018
accepted: 22 12 2018
pubmed: 5 2 2019
medline: 22 7 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

Do children conceived by ART have an increased risk of cancer? Overall, ART-conceived children do not appear to have an increased risk of cancer. Despite the increasing use of ART, i.e. IVF or ICSI worldwide, information about possible long-term health risks for children conceived by these techniques is scarce. A nationwide historical cohort study with prospective follow-up (median 21 years), including all live-born offspring from women treated with subfertility treatments between 1980 and 2001. All offspring of a nationwide cohort of subfertile women (OMEGA study) treated in one of the 12 Dutch IVF clinics or two fertility clinics. Of 47 690 live-born children, 24 269 were ART-conceived, 13 761 naturally conceived and 9660 were conceived naturally or through fertility drugs, but not by ART. Information on the conception method of each child and potential confounders were collected through the mothers' questionnaires and medical records. Cancer incidence was ascertained through linkage with The Netherlands Cancer Registry from 1 January 1989 until 1 November 2016. Cancer risk in ART-conceived children was compared with risks in naturally conceived children from subfertile women (hazard ratios [HRs]) and with the general population (standardized incidence ratios [SIRs]). The median follow-up was 21 years (interquartile range (IQR): 17-25) and was shorter in ART-conceived children (20 years, IQR: 17-23) compared with naturally conceived children (24 years, IQR: 20-30). In total, 231 cancers were observed. Overall cancer risk was not increased in ART-conceived children, neither compared with naturally conceived children from subfertile women (HR: 1.00, 95% CI 0.72-1.38) nor compared with the general population (SIR = 1.11, 95% CI: 0.90-1.36). From 18 years of age onwards, the HR of cancer in ART-conceived versus naturally conceived individuals was 1.25 (95% CI: 0.73-2.13). Slightly but non-significantly increased risks were observed in children conceived by ICSI or cryopreservation (HR = 1.52, 95% CI: 0.81-2.85; 1.80, 95% CI: 0.65-4.95, respectively). Risks of lymphoblastic leukemia (HR = 2.44, 95% CI: 0.81-7.37) and melanoma (HR = 1.86, 95% CI: 0.66-5.27) were non-significantly increased for ART-conceived compared with naturally conceived children. Despite the large size and long follow-up of the cohort, the number of cancers was rather small for subgroup analyses as cancer in children and young adults is rare. Overall, ART-conceived children do not appear to have an increased cancer risk after a median follow-up of 21 years. This large study provides important results, enabling physicians to better inform couples considering ART about the long-term safety of ART for their children. However, larger studies with prolonged follow-up are needed to investigate cancer risk in adults and in children conceived by ICSI and/or from cryopreserved embryos. This work was supported by The Dutch Cancer Society (NKI 2006-3631) which funded the OMEGA-women's cohort and Children Cancer Free (KIKA;147) which funded the OMEGA-offspring cohort. We declare no competing interests.

Identifiants

pubmed: 30715305
pii: 5306245
doi: 10.1093/humrep/dey394
pmc: PMC6443110
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

740-750

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD088393
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.

Références

Int J Technol Assess Health Care. 1999 Winter;15(1):52-65
pubmed: 10407596
Int J Epidemiol. 1999 Aug;28(4):631-9
pubmed: 10480689
Am J Hum Genet. 2003 Jan;72(1):156-60
pubmed: 12439823
J Med Genet. 2003 Jan;40(1):62-4
pubmed: 12525545
Am J Hum Genet. 2003 Jan;72(1):218-9
pubmed: 12549484
Lancet. 2003 Jun 7;361(9373):1975-7
pubmed: 12801753
J Anim Sci. 2004;82 E-Suppl:E53-62
pubmed: 15471815
J Med Genet. 2007 Feb;44(2):144-7
pubmed: 16950814
J Clin Endocrinol Metab. 2008 May;93(5):1682-8
pubmed: 18285409
Hum Mol Genet. 2009 Oct 15;18(20):3769-78
pubmed: 19605411
Hum Mol Genet. 2010 Jan 1;19(1):36-51
pubmed: 19805400
Pediatrics. 2010 Aug;126(2):270-6
pubmed: 20643723
Pediatr Blood Cancer. 2012 Jun;58(6):930-6
pubmed: 21618418
J Intern Med. 2011 Nov;270(5):414-20
pubmed: 21848664
Hum Reprod. 2011 Dec;26(12):3456-65
pubmed: 22031719
Pediatr Blood Cancer. 2013 Feb;60(2):301-8
pubmed: 22610722
Int J Cancer. 2013 Sep 1;133(5):1180-6
pubmed: 23404395
Fertil Steril. 2013 Jul;100(1):150-61
pubmed: 23562045
N Engl J Med. 2013 Nov 7;369(19):1819-27
pubmed: 24195549
Hum Reprod. 2014 Sep;29(9):2050-7
pubmed: 24990274
Int J Cancer. 2015 Apr 15;136(8):1931-9
pubmed: 25257918
Hum Reprod. 2015 May;30(5):1216-28
pubmed: 25743782
Pediatrics. 2016 Mar;137(3):e20152061
pubmed: 26908669
JAMA. 2016 Jul 19;316(3):300-12
pubmed: 27434442
Hum Reprod. 2016 Aug;31(8):1638-52
pubmed: 27496943
Pediatr Blood Cancer. 2017 Apr;64(4):
pubmed: 27748017
Acta Paediatr. 2017 May;106(5):698-709
pubmed: 28128867
Am J Obstet Gynecol. 2017 Mar;216(3):314.e1-314.e14
pubmed: 28153657
MMWR Surveill Summ. 2017 Feb 10;66(6):1-24
pubmed: 28182605
Hum Reprod. 2018 Jan 1;33(1):140-146
pubmed: 29106578
Int J Epidemiol. 1993 Jun;22(3):369-76
pubmed: 8359950

Auteurs

Mandy Spaan (M)

Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands.

Alexandra W van den Belt-Dusebout (AW)

Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands.

Marry M van den Heuvel-Eibrink (MM)

Princess Máxima Center for Pediatric Oncology, Lundlaan, Utrecht, The Netherlands.

Michael Hauptmann (M)

Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands.

Cornelis B Lambalk (CB)

Department of Obstetrics & Gynecology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, Amsterdam, The Netherlands.

Curt W Burger (CW)

Department of Gynecologic Oncology, Erasmus University Medical Center. Wytemaweg, Rotterdam, The Netherlands.

Flora E van Leeuwen (FE)

Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH